Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: Re-visiting glycated haemoglobin targets for cardiovascular disease prevention

Research output: Contribution to journalArticle

Abstract

Cardiovascular disease (CVD) is the leading cause of death among people with type 2 diabetes. Recent attention has focused on chronic hyperglycaemia as an additional risk factor in people with diabetes since their excess CVD risk is not entirely explained by traditional cardiovascular risk factors. Clinical trials of intensive glucose control to reduce CVD events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of chronic hyperglycaemia, predicts incident cardiovascular events. This review, which focuses on type 2 diabetes, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated haemoglobin (HbAlc) and CVD, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on-going clinical trials of intensive glycaemic control for CVD prevention.

Original languageEnglish (US)
Pages (from-to)792-798
Number of pages7
JournalDiabetes, Obesity and Metabolism
Volume9
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Hyperglycemia
Clinical Trials
Epidemiologic Studies
Cause of Death
Glucose

Keywords

  • Cardiovascular disease
  • Diabetes mellitus
  • Glycated haemoglobin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{8607232818014295ba09aaf3cce5d374,
title = "Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: Re-visiting glycated haemoglobin targets for cardiovascular disease prevention",
abstract = "Cardiovascular disease (CVD) is the leading cause of death among people with type 2 diabetes. Recent attention has focused on chronic hyperglycaemia as an additional risk factor in people with diabetes since their excess CVD risk is not entirely explained by traditional cardiovascular risk factors. Clinical trials of intensive glucose control to reduce CVD events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of chronic hyperglycaemia, predicts incident cardiovascular events. This review, which focuses on type 2 diabetes, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated haemoglobin (HbAlc) and CVD, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on-going clinical trials of intensive glycaemic control for CVD prevention.",
keywords = "Cardiovascular disease, Diabetes mellitus, Glycated haemoglobin",
author = "Golden, {Sherita Hill} and Elizabeth Selvin and Cunningham, {Kayla E.}",
year = "2007",
month = "11",
doi = "10.1111/j.1463-1326.2006.00673.x",
language = "English (US)",
volume = "9",
pages = "792--798",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Glycaemic status and cardiovascular disease in type 2 diabetes mellitus

T2 - Re-visiting glycated haemoglobin targets for cardiovascular disease prevention

AU - Golden, Sherita Hill

AU - Selvin, Elizabeth

AU - Cunningham, Kayla E.

PY - 2007/11

Y1 - 2007/11

N2 - Cardiovascular disease (CVD) is the leading cause of death among people with type 2 diabetes. Recent attention has focused on chronic hyperglycaemia as an additional risk factor in people with diabetes since their excess CVD risk is not entirely explained by traditional cardiovascular risk factors. Clinical trials of intensive glucose control to reduce CVD events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of chronic hyperglycaemia, predicts incident cardiovascular events. This review, which focuses on type 2 diabetes, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated haemoglobin (HbAlc) and CVD, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on-going clinical trials of intensive glycaemic control for CVD prevention.

AB - Cardiovascular disease (CVD) is the leading cause of death among people with type 2 diabetes. Recent attention has focused on chronic hyperglycaemia as an additional risk factor in people with diabetes since their excess CVD risk is not entirely explained by traditional cardiovascular risk factors. Clinical trials of intensive glucose control to reduce CVD events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of chronic hyperglycaemia, predicts incident cardiovascular events. This review, which focuses on type 2 diabetes, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated haemoglobin (HbAlc) and CVD, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on-going clinical trials of intensive glycaemic control for CVD prevention.

KW - Cardiovascular disease

KW - Diabetes mellitus

KW - Glycated haemoglobin

UR - http://www.scopus.com/inward/record.url?scp=35048867772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35048867772&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2006.00673.x

DO - 10.1111/j.1463-1326.2006.00673.x

M3 - Article

C2 - 17924863

AN - SCOPUS:35048867772

VL - 9

SP - 792

EP - 798

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -